Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 348
Gene Symbol: APOE
APOE
0.020 Biomarker phenotype BEFREE Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. 8971103 1996
Entrez Id: 5663
Gene Symbol: PSEN1
PSEN1
0.010 GeneticVariation phenotype BEFREE However, in this family, an individual whose child carries the PS1 mutation died at age 67 years free from cognitive symptoms, indicating a very late age at onset or nonpenetration of the disease. 9605727 1998
Entrez Id: 1270
Gene Symbol: CNTF
CNTF
0.010 Biomarker phenotype BEFREE These results support the hypothesis that CNTF infusion into the striatum of HD patients not only could block the degeneration of neurons but also alleviated motor and cognitive symptoms associated with persistent neuronal dysfunction. 10834619 2000
Entrez Id: 590
Gene Symbol: BCHE
BCHE
0.020 Biomarker phenotype BEFREE Currently available cholinesterase inhibition therapy targets the cognitive symptoms. 12614093 2003
Entrez Id: 345643
Gene Symbol: MCIDAS
MCIDAS
0.010 GeneticVariation phenotype BEFREE Patients homozygous for H63D exhibited trends towards accelerated MCI-to-AD conversion rates and a subset of younger individuals (aged 55-75) exhibited earlier onset of cognitive symptoms relative to wild-type hfe and H63D heterozygotes. 15013567 2004
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.030 GeneticVariation phenotype BEFREE The dopamine D2 receptor (DRD2) Ser311Cys polymorphism may also play a role in determining risperidone efficacy for positive, negative and cognitive symptoms, the DRD2 Ins-A2/Del-A1 diplotype may predict better risperidone response, and the DRD3 Ser311Cys variant may affect general treatment response of several atypical agents. 15882132 2005
Entrez Id: 958
Gene Symbol: CD40
CD40
0.010 GeneticVariation phenotype BEFREE Deficits in P50 auditory gating are associated with attentional impairment and may contribute to cognitive symptoms and perceptual disturbances. 17349863 2007
Entrez Id: 4790
Gene Symbol: NFKB1
NFKB1
0.010 GeneticVariation phenotype BEFREE Deficits in P50 auditory gating are associated with attentional impairment and may contribute to cognitive symptoms and perceptual disturbances. 17349863 2007
Entrez Id: 8874
Gene Symbol: ARHGEF7
ARHGEF7
0.010 GeneticVariation phenotype BEFREE Deficits in P50 auditory gating are associated with attentional impairment and may contribute to cognitive symptoms and perceptual disturbances. 17349863 2007
Entrez Id: 115482723
Gene Symbol: H3P40
H3P40
0.010 GeneticVariation phenotype BEFREE Deficits in P50 auditory gating are associated with attentional impairment and may contribute to cognitive symptoms and perceptual disturbances. 17349863 2007
Entrez Id: 51008
Gene Symbol: ASCC1
ASCC1
0.010 GeneticVariation phenotype BEFREE Deficits in P50 auditory gating are associated with attentional impairment and may contribute to cognitive symptoms and perceptual disturbances. 17349863 2007
Entrez Id: 84062
Gene Symbol: DTNBP1
DTNBP1
0.010 Biomarker phenotype BEFREE To date, DTNBP1 has provided the greatest evidence of illness modification, as associations with negative and cognitive symptoms and worse outcome have been published in independent samples. 18474210 2008
Entrez Id: 4137
Gene Symbol: MAPT
MAPT
0.020 Biomarker phenotype BEFREE Biochemical modifications of tau proteins have been proposed to be among the earliest neurobiological changes in Alzheimer's disease (AD) and correlate better with cognitive symptoms than do beta-amyloid plaques. 18511295 2008
Entrez Id: 5141
Gene Symbol: PDE4A
PDE4A
0.010 Biomarker phenotype BEFREE Insights into the multiple brain processes to which PDEs contribute are emerging from the phenotype of genetically engineered mice that lack activity of specific PDEs (knockout mice), as well as from in vitro and in vivo studies with PDE inhibitors.This article provides a brief overview of recent studies implicating PDE inhibition, focusing on PDE4 and PDE10, as targets for treating the positive, negative or cognitive symptoms associated with schizophrenia. 18998737 2008
Entrez Id: 10743
Gene Symbol: RAI1
RAI1
0.300 Biomarker phenotype CTD_human Distorted Mendelian transmission as a function of genetic background in Rai1-haploinsufficient mice. 19116176 2009
Entrez Id: 1139
Gene Symbol: CHRNA7
CHRNA7
0.300 Biomarker phenotype CTD_human A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. 19898479 2009
Entrez Id: 348
Gene Symbol: APOE
APOE
0.020 GeneticVariation phenotype BEFREE Importantly, the ApoE genotype seems to influence cortical activation in patients with aMCI and to a lesser degree in healthy controls as well, who are without any cognitive symptoms. 21192235 2011
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.030 GeneticVariation phenotype BEFREE These findings suggest that DRD2 polymorphisms are associated with the therapeutic effects of risperidone as they relate to positive symptoms and that plasma drug concentrations are associated with overall symptoms as well as excitement and cognitive symptoms. 21869689 2011
Entrez Id: 407046
Gene Symbol: MIR9-1
MIR9-1
0.300 Biomarker phenotype CTD_human MicroRNAs control neurobehavioral development and function in zebrafish. 22253472 2012
Entrez Id: 4803
Gene Symbol: NGF
NGF
0.300 Therapeutic phenotype CTD_human "Intranasal ""painless"" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice." 22666365 2012
Entrez Id: 3356
Gene Symbol: HTR2A
HTR2A
0.020 Biomarker phenotype BEFREE Furthermore, identification of a role for a 5-HT(2) receptor agonist as a cognition-enhancing agent in mutant mice suggests a potential avenue to explore for the personalized treatment of cognitive symptoms in humans with reduced 5-HT synthesis and TPH2 polymorphisms. 24196946 2014
Entrez Id: 121278
Gene Symbol: TPH2
TPH2
0.010 GeneticVariation phenotype BEFREE Furthermore, identification of a role for a 5-HT(2) receptor agonist as a cognition-enhancing agent in mutant mice suggests a potential avenue to explore for the personalized treatment of cognitive symptoms in humans with reduced 5-HT synthesis and TPH2 polymorphisms. 24196946 2014
Entrez Id: 2289
Gene Symbol: FKBP5
FKBP5
0.300 Biomarker phenotype CTD_human Placental FKBP5 genetic and epigenetic variation is associated with infant neurobehavioral outcomes in the RICHS cohort. 25115650 2014
Entrez Id: 6898
Gene Symbol: TAT
TAT
0.010 GeneticVariation phenotype BEFREE Results confirm that the C31S dicysteine motif substitution of the Tat protein does not appreciably moderate neuropsychological outcomes in clade C. Further, these findings highlight the importance of clinical management of cognitive symptoms among individuals infected with this viral clade worldwide. 25366660 2014
Entrez Id: 6403
Gene Symbol: SELP
SELP
0.300 Biomarker phenotype CTD_human Platelet hyperactivity, neurobehavioral symptoms and depression among Indian women chronically exposed to low level of arsenic. 25451969 2014